Ginkgo Bioworks (NYSE:DNA – Get Free Report) and Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.
Institutional & Insider Ownership
78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Ginkgo Bioworks and Adaptive Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ginkgo Bioworks | -298.78% | -58.54% | -34.24% |
| Adaptive Biotechnologies | -110.13% | -62.06% | -26.82% |
Risk & Volatility
Analyst Recommendations
This is a summary of recent ratings for Ginkgo Bioworks and Adaptive Biotechnologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ginkgo Bioworks | 3 | 1 | 1 | 0 | 1.60 |
| Adaptive Biotechnologies | 0 | 1 | 3 | 0 | 2.75 |
Ginkgo Bioworks currently has a consensus target price of $4.58, indicating a potential downside of 28.18%. Adaptive Biotechnologies has a consensus target price of $6.50, indicating a potential upside of 27.95%. Given Adaptive Biotechnologies’ stronger consensus rating and higher possible upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Ginkgo Bioworks.
Valuation & Earnings
This table compares Ginkgo Bioworks and Adaptive Biotechnologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ginkgo Bioworks | $184.34 million | 1.92 | -$892.87 million | ($13.08) | -0.49 |
| Adaptive Biotechnologies | $170.28 million | 4.40 | -$225.25 million | ($1.34) | -3.79 |
Adaptive Biotechnologies has lower revenue, but higher earnings than Ginkgo Bioworks. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.
Summary
Adaptive Biotechnologies beats Ginkgo Bioworks on 10 of the 14 factors compared between the two stocks.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
